Apogenix
Latest round
- Series B
Last raised
- Apr 2008
Total raised
- $62M
Investors
- 1
About Apogenix
Apogenix is engaged in the development of immunotherapies targeting cancer and viral infections. The company was founded in Heidelberg, Germany. Its CEO is Thomas Hoeger.Apogenix specializes in developing innovative immunotherapeutics aimed at addressing cancer and viral infections, including COVID-19. Its core product, asunercept, is currently in clinical development for treating solid tumors, malignant hematological diseases, and COVID-19. Utilizing the HERA-ligand technology platform, asunercept targets TNFSF-dependent signaling pathways crucial for regulating the immune response, aiming to reduce lymphopenia and inflammatory cell death while restoring anti-tumor immunity.Apogenix's revenue model is structured around partnerships and collaborations with healthcare providers and research institutions, focusing on clinical trials and commercialization of its immunotherapeutic products. Transactions typically involve agreements for treatment provision, including upfront payments, milestone payments based on clinical progress, and royalties from future sales.
Who invested in Apogenix
1 investor across 2 rounds
See all investors in Apogenix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Apogenix
Who invested in Apogenix?
Apogenix has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Apogenix raised?
Apogenix has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Apogenix last raise money?
Apogenix's most recent round on record is a Series B, in Apr 2008.
What does Apogenix do?
Apogenix is engaged in the development of immunotherapies targeting cancer and viral infections.
Where is Apogenix headquartered?
Apogenix is headquartered in Heidelberg, Germany.
Which VCs invest in companies like Apogenix?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Apogenix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Apogenix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.